A partnership between Medtronic and BioIntelliSense is shining a spotlight on the wearables space. The collaboration calls for Dublin-based Medtronic to distribute BioIntelliSense’s BioButton multi-parameter wearable, that is used for continuous, connected monitoring.

Terms of the deal were not disclosed.

The BioButton medical grade device, measures up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, and heart rate at rest.

This device, combined with advanced analytics, has the potential to help enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge.

The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings.

"Our vision is to empower clinicians and patients with actionable insights to personalize care — anytime, anywhere," said Frank Chan, PhD, president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before."